Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03255824 · ClinicalTrials.gov registry record · Phase 4

A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation

A Phase 4 study, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 4
Development phase
144
Enrollment target

NCT03255824: Completed Phase 4 study, sponsored by Montefiore Medical Center.

NCT03255824 is a Phase 4 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 144 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03255824, a Phase 4 study, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
144 participants
Enrollment target

Study Summary

Hypothesis: A combination of midazolam with dexmedetomidine for sedation during third molar surgery will provide 1) superior patient satisfaction, 2) superior operator satisfaction and 3) no significant hemodynamic or respiratory changes when compared to a sedation combination of midazolam, fentanyl and propofol for sedation during third molar surgery.

Primary Outcome

To compare the groups regarding the number of respiratory events requiring intervention, described as: Chin lift/jaw thrust, Tongue thrust, Yankauer suctioning, Positive pressure oxygen administration, Placement of an oral or nasal airway.

Interventions

  • DRUG Dexmedetomidine and Midazolam
  • DRUG Propofol, Midazolam, and Fentanyl

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2018-03-20
Est. Completion 2019-12-27
Phase Phase 4
Montefiore Medical Center

345 total trials

What the finished NCT03255824 record still lists

NCT03255824 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine and Midazolam is the first listed.

NCT03255824 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03255824 about?

NCT03255824 is a clinical study titled "A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation". Hypothesis: A combination of midazolam with dexmedetomidine for sedation during third molar surgery will provide 1) superior patient satisfaction, 2) superior operator satisfaction and 3) no significant hemodynamic or respiratory changes when compared to a sedation combination of midazolam, fentanyl...

What is the current status of trial NCT03255824?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 144 participants. The study started on 2018-03-20. Estimated completion is 2019-12-27.

What interventions are being tested in trial NCT03255824?

The interventions under investigation include: Dexmedetomidine and Midazolam (DRUG), Propofol, Midazolam, and Fentanyl (DRUG).

Who is sponsoring clinical trial NCT03255824?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03255824's enrollment target sits among peer trials

144 577th of 2000 higher than 1,421 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03255824, the US trial registry maintained by the National Library of Medicine. NCT03255824 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.